Bellicum Pharmaceuticals, Inc. (BLCM) Stock Increasing in Aftermarket Despite Clear Reason.

Bellicum Pharmaceuticals, Inc. (BLCM) is a leading innovative clinical stage pharmaceutical company focusing on the treatment of hematological cancers and solid tumors using cellular immunotherapy. Some of the lead product candidates of the company include BPX-601 and BPX-603. They are used for treatment of solid tumors expressing prostrate stem cell antigen and human epidermal growth factor receptor 2 antigen.

The price of BLCM stock during the regular trading on December 31, 2021 was $1.49 with a significant incline of 4.20%. At last check in the aftermarket, the stock was further up by 6.71%.

BLCM: Events and Happenings

On December 13, 2021, BLCM reported about receipt of the notification from the Nasdaq, stated that the company that it has regained compliance with Listing Rule 5550(b)(1). The rule required the shareholder’s equity of minimum $2.5 million for constant listing of the company’s common stock. The notification came after the BLCM’s accomplishment of underwritten private placement of equity securities for gross proceeds of up to $35.0 million.

On December 06, 2021, BLCM reported promising interim outcomes from its Phase clinical trials of 1/2 GoCAR-T. The company also entered into a $35 million collaboration of private placement of equity securities with two investment funds. Financing proceeds were utilized for the sustenance of clinical development of lead drug candidates.

BLCM: Key Financials

On November 04, 2021, BLCM announced financial results for the third quarter 2021 ended September 30, 2021. Some of the key highlights are as follows.

Revenue and Assets

The revenue generated for the third quarter 2021 was $5.0 million as compared to the same quarter of 2020 when the revenue was nil. The current assets of the company for Q3 2021 were $19.2 million.

Net Income/Loss per Share

Basic and diluted net loss per share for third quarter 2020 was $0.88 million or $0.18 per share. The company reported net income of $1.2 million or $0.08 per share (basic) and $0.07 per share (diluted).

On September 03, 2021, BLCM reported that the company’s executives participated in the Virtual 23rd Annual H.C. Wainwright Global Investment Conference held on September 13, 2021. On September 01, 2021, BLCM and MD Anderson Cancer Center co-announced about their new licensing contract. The contract covered intellectual property and technology rights of the company’s CaspaCIDe safety switch and using rimiducid for the activation of safety switch. Under this contract terms, MD Anderson had the opportunity to incorporate CaspaCIDe into cellular treatment platforms.


BLCM’s stock is 11% down the past month and the current incline in the stock price is the result of uncertainty in the market and no clear reason can be assumed. The stockholders and the investors are likely to increase their investment input in the company because of far-reaching impact of company’s policies, as suggested by the experts.